Retrophin, Inc. (RTRX): Price and Financial Metrics

Retrophin, Inc. (RTRX): $24.25

0.11 (-0.45%)

POWR Rating

Component Grades








Add RTRX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

RTRX Price/Volume Stats

Current price $24.25 52-week high $24.96
Prev. close $24.36 52-week low $8.98
Day low $24.04 Volume 378,900
Day high $24.74 Avg. volume 412,277
50-day MA $20.67 Dividend yield N/A
200-day MA $17.78 Market Cap 1.24B

RTRX Stock Price Chart Interactive Chart >

Retrophin, Inc. (RTRX) Company Bio

Retrophin focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. The company was founded in 2011 and is based in San Diego, California.

RTRX Latest News Stream

Event/Time News Detail
Loading, please wait...

RTRX Latest Social Stream

Loading social stream, please wait...

View Full RTRX Social Stream

Latest RTRX News From Around the Web

Below are the latest news stories about Retrophin Inc that investors may wish to consider to help them evaluate RTRX as an investment opportunity.

Retrophin enrolls patients for the study of sparsentan in IgA nephropathy

Retrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achieving this important enrollment milestone...

Seeking Alpha | September 21, 2020

BofA bullish on Retrophin, sees 56% upside

BofA analyst Scott Puckhaber has initiated coverage on Retrophin ([[RTRX]] +3.9%) with a Buy rating and $30 (56% upside) price target.Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2...

Seeking Alpha | August 24, 2020

Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following…

GlobeNewswire | August 3, 2020

Retrophin Reports Second Quarter 2020 Financial Results

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now…

GlobeNewswire | July 30, 2020

Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Read More 'RTRX' Stories Here

RTRX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year 30.87%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -37.25%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!